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Parkinson’s disease (PD) is traditionally regarded as a mo-
tor or a movement disorder. In recent years, however, an
increased interest has been directed to its nonmotor symp-
toms as they seem to determine signiﬁcant disability at all
stages of the disease. Some PD patients consider their non-
motor symptoms even more disabling than motor signs.
Among these nonmotor symptoms, neuropsychiatric syn-
dromes (or behavioral and psychological symptoms) are of
paramount importance. They include a wide array of syn-
dromes such as anxiety, depression, psychosis, impulse con-
trol disorders, apathy, and cognitive dysfunction. Their path-
ogenesis in PD is rather complex, involving neurodegen-
erative, drug-related, and psychological mechanisms. Their
recognition and management represent a great challenge.
The paper by R. de la Fuente-Fern´ andez presents a stag-
ing model named PD-related frontostriatal cognitive dys-
function (PDFCD) that provides a clinical and hypothesis-
testing framework for neuropsychiatric syndromes in PD.
De La Fuente-Fernandez’s PDFCD model proposes three
stagesbasedonthesequentialprocessofdopaminedepletion
occurring in diﬀerent regions of the striatum (stages I and
II) and the frontal cortex (stage III). Therefore, PD patients
would present executive dysfunction and mental fatigue
(stage I), depression/anxiety (stage IIa), apathy/pain (stage
IIb), and dementia (stage III).
The paper by J. Calleo et al. summarizes the current liter-
ature on the cognitive rehabilitation programs in PD pa-
tients. Despite limited available data and heterogeneity of
motor and nonmotor symptoms in PD, cognitive rehabili-
tation seems to be promising in this context.
ThepaperbyY.BogdanovaandA.Cronin-Golomb1pre-
sents an original study that assessed cognitive correlates of
anxiety and apathy in PD patients. In comparison with
matched controls, PD patients exhibited higher levels of anx-
iety and apathy which were correlated with disease duration.
Interestingly, anxiety and apathy correlated diﬀerently with
cognitive functions. The question remains open whether the
treatment of both conditions impacts on cognitive func-
tioning in PD.
Untilrecently,moststudieshavefocusedontheimpactof
motor disability and depressive symptoms on the quality of
life of PD patients, neglecting the role of anxiety. The paper
by K. K. Hanna and A. Cronin-Golomb addressed this issue,
reporting that anxiety, more than depressive, cognitive, and
motor symptoms, signiﬁcantly aﬀected quality of life in PD.
Dopaminergic strategies remain the mainstay of PD
treatment. However, they are frequently associated with neu-
ropsychiatricsyndromes,notablypsychosis.Alternativether-
apeutic options have been searched in the last years, and
adenosine A2A receptor antagonists seem to be very promis-
ing. The paper by C. J. Bleickardt et al. demonstrates that, in
comparisonwithdopamine receptoragonists,adenosine A2A
antagonistsexhibitbetterneuropsychiatricproﬁlesastheydo
not interfere with prepulse inhibition in rodents (a model of
psychosis).2 Parkinson’s Disease
The paper by E. C. Lauterbach et al. presents a compre-
hensive review of the neuroprotective eﬀects of the psycho-
tropic drugs used in PD.
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